Organon patents expiration
1. Clarinex patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214684 | ORGANON | Methods for the treatment of allergic rhinitis |
Dec, 2014
(9 years ago) | |
| US7214683 | ORGANON | Compositions of descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
| US7211582 | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
| US5607697 | ORGANON | Taste masking microparticles for oral dosage forms |
Jun, 2015
(8 years ago) | |
|
US7214683 (Pediatric) | ORGANON | Compositions of descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
|
US7214684 (Pediatric) | ORGANON | Methods for the treatment of allergic rhinitis |
Jun, 2015
(8 years ago) | |
|
US7211582 (Pediatric) | ORGANON | Methods for treating urticaria using descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
|
US5607697 (Pediatric) | ORGANON | Taste masking microparticles for oral dosage forms |
Dec, 2015
(8 years ago) | |
| US6100274 | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(4 years ago) | |
| US7405223 | ORGANON | Treating allergic and inflammatory conditions |
Jul, 2019
(4 years ago) | |
|
US6100274 (Pediatric) | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(4 years ago) | |
|
US7405223 (Pediatric) | ORGANON | Treating allergic and inflammatory conditions |
Jan, 2020
(4 years ago) | |
| US7618649 | ORGANON | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
|
US7618649 (Pediatric) | ORGANON | Extended release oral dosage composition |
Jun, 2021
(2 years ago) | |
Drugs and Companies using DESLORATADINE ingredient
Market Authorisation Date: 21 December, 2001
Treatment: Treatment of allergic rhinitis; Treatment of chronic idiopathic urticaria; Administering desloratadine to treat the symptoms of perennial allergic rhinitis, seasonal allergic rhinitis, or chronic idio...
Dosage: TABLET;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
CLARINEX family patents
2. Clarinex D 24 Hour patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7214683 | ORGANON | Compositions of descarboethoxyloratadine |
Dec, 2014
(9 years ago) | |
| US7214684 | ORGANON | Methods for the treatment of allergic rhinitis |
Dec, 2014
(9 years ago) | |
|
US7214684 (Pediatric) | ORGANON | Methods for the treatment of allergic rhinitis |
Jun, 2015
(8 years ago) | |
|
US7214683 (Pediatric) | ORGANON | Compositions of descarboethoxyloratadine |
Jun, 2015
(8 years ago) | |
| US6100274 | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jul, 2019
(4 years ago) | |
|
US6100274 (Pediatric) | ORGANON | 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions |
Jan, 2020
(4 years ago) | |
| US7618649 | ORGANON | Extended release oral dosage composition |
Dec, 2020
(3 years ago) | |
|
US7618649 (Pediatric) | ORGANON | Extended release oral dosage composition |
Jun, 2021
(2 years ago) | |
| US6979463 | ORGANON | Stable extended release oral dosage composition |
Mar, 2022
(2 years ago) | |
| US7820199 | ORGANON | Stable extended release oral dosage composition |
Mar, 2022
(2 years ago) | |
|
US7820199 (Pediatric) | ORGANON | Stable extended release oral dosage composition |
Sep, 2022
(1 year, 6 months ago) | |
Drugs and Companies using DESLORATADINE; PSEUDOEPHEDRINE SULFATE ingredient
Market Authorisation Date: 03 March, 2005
Treatment: Treatment of allergic rhinitis; A method of treating nasal and non-nasal symptoms of seasonal allergic rhinitis
Dosage: TABLET, EXTENDED RELEASE;ORAL
CLARINEX D 24 HOUR family patents
3. Fosamax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5358941 | ORGANON | Dry mix formulation for bisphosphonic acids with lactose |
Dec, 2012
(11 years ago) | |
| US5681590 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US6090410 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US6194004 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
|
US5358941 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids with lactose |
Jun, 2013
(10 years ago) | |
|
US6090410 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US5681590 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US6194004 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
Drugs and Companies using ALENDRONATE SODIUM ingredient
Market Authorisation Date: 25 April, 1997
Treatment: NA
Dosage: TABLET;ORAL
FOSAMAX family patents
4. Implanon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
IMPLANON family patents
5. Liptruzet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5969156 | ORGANON | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jul, 2016
(7 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
| US5686104 | ORGANON | Stable oral CI-981 formulation and process of preparing same |
Nov, 2014
(9 years ago) | |
|
US5686104 (Pediatric) | ORGANON | Stable oral CI-981 formulation and process of preparing same |
May, 2015
(8 years ago) | |
|
US5969156 (Pediatric) | ORGANON | Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
Jan, 2017
(7 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Combination(NC) | May 03, 2016 |
Drugs and Companies using ATORVASTATIN CALCIUM; EZETIMIBE ingredient
Market Authorisation Date: 03 May, 2013
Treatment: For the treatment of primary hyperlipidemia, mixed hyperlipidemia or homozygous familial hypercholesterolemia
Dosage: TABLET;ORAL
LIPTRUZET family patents
6. Maxalt-mlt patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5602162 (Pediatric) | ORGANON | Imidazole, triazole and tetrazole derivatives |
Jul, 2012
(11 years ago) | |
|
US5298520 (Pediatric) | ORGANON | Triazole containing indole derivatives |
Dec, 2012
(11 years ago) | |
| US5457895 | ORGANON | Method of identifying freeze-dried dosage forms |
Oct, 2013
(10 years ago) | |
|
US5457895 (Pediatric) | ORGANON | Method of identifying freeze-dried dosage forms |
Apr, 2014
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 16, 2015 |
| New Patient Population(NPP) | Dec 16, 2014 |
Drugs and Companies using RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 29 June, 1998
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
MAXALT-MLT family patents
7. Nexplanon patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8888745 | ORGANON | Applicator for inserting an implant |
Aug, 2026
(2 years from now) | |
| US10821277 | ORGANON | Kit for and method of assembling an applicator for inserting an implant |
May, 2027
(3 years from now) | |
| US8722037 | ORGANON | X-ray visible drug delivery device |
Sep, 2027
(3 years from now) | |
| US9757552 | ORGANON | Applicator for inserting an implant |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 31, 2014 |
Drugs and Companies using ETONOGESTREL ingredient
Market Authorisation Date: 17 July, 2006
Treatment: Prevention of pregnancy
Dosage: IMPLANT;IMPLANTATION
NEXPLANON family patents
8. Propecia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5886184 | ORGANON | Finasteride processes |
Nov, 2012
(11 years ago) | |
| US5547957 | ORGANON | Method of treating androgenic alopecia with 5-α reductase inhibitors |
Oct, 2013
(10 years ago) | |
| US5571817 | ORGANON | Methods of treating androgenic alopecia with finasteride [17β-N-mono-substituted-carbamoyl-4-aza-5-α-androst-1-en-ones] |
Nov, 2013
(10 years ago) | |
Drugs and Companies using FINASTERIDE ingredient
Market Authorisation Date: 19 December, 1997
Treatment: Treating male pattern baldness with 0.05 to 3.0mg/day; Treatment of androgenic alopecia by oral administration drug substance
Dosage: TABLET;ORAL
PROPECIA family patents
9. Proscar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5886184 | ORGANON | Finasteride processes |
Nov, 2012
(11 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5942519 | ORGANON | Prevention of precipitated acute urinary retention |
Oct, 2018
(5 years ago) | |
Drugs and Companies using FINASTERIDE ingredient
Market Authorisation Date: 19 June, 1992
Treatment: Treating precipitated acute urinary retention with finasteride
Dosage: TABLET;ORAL
PROSCAR family patents
10. Singulair patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5565473 (Pediatric) | ORGANON | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
Aug, 2012
(11 years ago) | |
| US8007830 | ORGANON | Granule formation |
Oct, 2022
(1 year, 6 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Mar 26, 2015 |
Drugs and Companies using MONTELUKAST SODIUM ingredient
Market Authorisation Date: 03 March, 2000
Treatment: NA
Dosage: TABLET, CHEWABLE;ORAL; GRANULE;ORAL; TABLET;ORAL
SINGULAIR family patents
11. Vytorin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
|
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE; SIMVASTATIN ingredient
Market Authorisation Date: 23 July, 2004
Treatment: Treatment of primary hypercholesterolemia, mixed hyperlipidemia and/or homozygous familial hypercholesterolemia (hofh); To reduce plasma cholesterol levels in a mammal
Dosage: TABLET;ORAL
VYTORIN family patents
12. Zetia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE37721 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| USRE42461 | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5846966 | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Sep, 2013
(10 years ago) | |
|
US5846966 (Pediatric) | ORGANON | Combinations of hydroxy-substituted azetidinone compounds and HMG CoA Reductase Inhibitors |
Mar, 2014
(10 years ago) | |
|
USRE37721 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
|
USRE42461 (Pediatric) | ORGANON | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
Apr, 2017
(7 years ago) | |
| US7030106 | ORGANON | Sterol absorption inhibitor compositions |
Jan, 2022
(2 years ago) | |
|
US7030106 (Pediatric) | ORGANON | Sterol absorption inhibitor compositions |
Jul, 2022
(1 year, 9 months ago) | |
| US7612058 | ORGANON | Methods for inhibiting sterol absorption |
Oct, 2025
(1 year, 6 months from now) | |
|
US7612058 (Pediatric) | ORGANON | Methods for inhibiting sterol absorption |
Apr, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Dec 05, 2011 |
| M(M-109) | Jan 24, 2015 |
Drugs and Companies using EZETIMIBE ingredient
Market Authorisation Date: 25 October, 2002
Treatment: To reduce plasma cholesterol levels by admin ezetimibe in combo with cholesterol biosynthesis inhib selected from group consisting of hmg coa reductase inhibitors incl simvastatin; Reduction of elevat...
Dosage: TABLET;ORAL
ZETIA family patents